scholarly journals Ewing's sarcoma with distant metastasis: A brief note on management and emerging therapies

2019 ◽  
Vol 9 (3) ◽  
Author(s):  
Girish Gulab Meshram ◽  
Neeraj Kaur ◽  
Kanwaljeet Singh Hura
Keyword(s):  
High Risk ◽  
Distant Metastasis ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Molecular Targets ◽  
Chemotherapeutic Agents ◽  
Young Population ◽  
Emerging Therapies ◽  
The Right ◽  
High Risk Case

Ewing’s sarcoma is an aggressive fatal malignancy of bones and soft-tissue. It predominantly affects the young population, with a worldwide incidence of three cases per million. The pelvis, extremities, and ribs are the most common sites. We present a case of massive Ewing’s sarcoma of the right femur with metastasis to bones and lungs. The patient was treated with chemotherapy. However, he succumbed to his illness before completion of therapy. In conclusion, Ewing’s sarcoma with distant metastasis is a high risk case with poor prognosis. Integrating novel molecular targets with conventional chemotherapeutic agents holds a promise for high-risk Ewing’s sarcoma patients.

scholarly journals A case of Extraskeletal Ewing's sarcoma arising from the right chest wall.

1999 ◽  
Vol 38 (6) ◽  
pp. 613-614 ◽  
Author(s):  
Hirofumi SAKURAI ◽  
Akiko KOBAYASHI ◽  
Tetsurou ICHIKAWA ◽  
Hiroshi HASHIMOTO
Keyword(s):  
Chest Wall ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Extraskeletal Ewing’S Sarcoma ◽  
The Right

Brain and bone scans in primary Ewing's sarcoma of the petrous bone

1976 ◽  
Vol 44 (5) ◽  
pp. 608-612 ◽  
Author(s):  
Pete M. Fitzer ◽  
William R. Steffey
Keyword(s):  
Bone Scan ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Petrous Bone ◽  
Diagnosis And Treatment ◽  
Content Type ◽  
Brain Scan ◽  
Bone Scans ◽  
The Right ◽  
Fine Print

✓ The authors present a case in which primary Ewing's sarcoma of the right petrous pyramid in a 9-year-old girl showed no uptake on a 99mTc-pertechnetate nuclide angiogram. Intense uptake was present on a 99mTc-polyphosphate bone scan, but a static brain scan was only minimally abnormal. The diagnosis and treatment of Ewing's sarcoma are reviewed.

scholarly journals Delayed Diagnosis of Ewing's Sarcoma of the Right Humerus Initially Treated as Chronic Osteomyelitis: A Case Report

2005 ◽  
Vol 13 (1) ◽  
pp. 88-92 ◽  
Author(s):  
BPB Tow ◽  
MH Tan
Keyword(s):  
Case Report ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Chronic Osteomyelitis ◽  
Delayed Diagnosis ◽  
Delay In Diagnosis ◽  
Limited Stage ◽  
History Of ◽  
Anti Inflammatory ◽  
The Right

We report a case of limited stage Ewing's sarcoma which was initially treated as chronic osteomyelitis for 3 years. A 24-year-old man presented with a one-week history of pain in the right arm and fever, with histology suggestive of osteomyelitis of the affected humerus. He developed multiple relapses of pain and fever; each episode responded to antibiotic treatment. A second biopsy was performed 3 years later and confirmed a diagnosis of Ewing's sarcoma. Despite a 3-year delay in diagnosis, the disease remained localised. This case report highlights an atypical facet of the natural history of Ewing's sarcoma: a response to antibiotic and anti-inflammatory agents, and the limited stage of the disease despite a misdiagnosis of 3 years. This suggests the possibility that anti-inflammatory agents exert an inhibitory effect on the tumour growth. We also highlight the newer histologic and immunologic staining used in the diagnosis of Ewing's sarcoma.

scholarly journals Myeloablative therapy against high risk Ewing's sarcoma: A single institution experience and literature review

2011 ◽  
Vol 16 (5) ◽  
pp. 163-169
Author(s):  
Jose Luis Lopez ◽  
Concepcion Pérez ◽  
Catalina Marquez ◽  
Patricia Cabrera ◽  
Jose Maria Perez ◽  
...  
Keyword(s):  
High Risk ◽  
Literature Review ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Single Institution

Long-lasting multiagent chemotherapy in adult high-risk Ewing’s sarcoma of bone

2008 ◽  
Vol 26 (3) ◽  
pp. 276-286 ◽  
Author(s):  
Selmin Ataergin ◽  
Ahmet Ozet ◽  
Luis Solchaga ◽  
Mustafa Turan ◽  
Murat Beyzadeoglu ◽  
...  
Keyword(s):  
High Risk ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Multiagent Chemotherapy

Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients

2008 ◽  
Vol 26 (27) ◽  
pp. 4385-4393 ◽  
Author(s):  
Michael Paulussen ◽  
Alan W. Craft ◽  
Ian Lewis ◽  
Allan Hackshaw ◽  
Carolyn Douglas ◽  
...  
Keyword(s):  
High Risk ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Similar Efficacy ◽  
Hazard Ratio ◽  
Hazard Ratios ◽  
Risk Patients ◽  
First Recurrence ◽  
To Receive ◽  
Standard Risk

Purpose The European Intergroup Cooperative Ewing's Sarcoma Study investigated whether cyclophosphamide has a similar efficacy as ifosfamide in standard-risk (SR) patients and whether the addition of etoposide improves survival in high-risk (HR) patients. Patients and Methods SR patients (localized tumors, volume <100 mL) were randomly assigned to receive four courses of vincristine, dactinomycin, ifosfamide, and doxorubicin (VAIA) induction therapy followed by 10 courses of either VAIA or vincristine, dactinomycin, cyclophosphamide, and doxorubicin (VACA; cyclophosphamide replacing ifosfamide). HR patients (volume ≥100 mL or metastases) were randomly assigned to receive 14 courses of either VAIA or VAIA plus etoposide (EVAIA). Outcome measures were event-free survival (EFS; defined as the time to first recurrence, progression, second malignancy, or death) and overall survival (OS). Results A total of 647 patients were randomly assigned: 79 SR patients were assigned to VAIA, 76 SR patients were assigned to VACA, 240 HR were assigned to VAIA, and 252 HR patients were assigned to EVAIA. The median follow-up was 8.5 years. In the SR group, the hazard ratios (VACA v VAIA) for EFS and OS were 0.91 (95% CI, 0.55 to 1.53) and 1.08 (95% CI, 0.58 to 2.03), respectively. There was a higher incidence of hematologic toxicities in the VACA arm. In the HR group, the EFS and OS hazard ratios (EVAIA v VAIA) indicated a 17% reduction in the risk of an event (95% CI, −35% to 5%; P = .12) and 15% reduction in dying (95% CI, −34% to 10%), respectively. The effect seemed greater among patients without metastases (hazard ratio = 0.79; P = .16) than among those with metastases (hazard ratio = 0.96; P = .84). Conclusion Cyclophosphamide seemed to have a similar effect on EFS and OS as ifosfamide in SR patients but was associated with increased toxicity. In HR patients, the addition of etoposide seemed to be beneficial.

scholarly journals Discovery and Validation of a Compound to Target Ewing’s Sarcoma

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1553
Author(s):  
Ellie Esfandiari Nazzaro ◽  
Fahad Y. Sabei ◽  
Walter K. Vogel ◽  
Mohamad Nazari ◽  
Katelyn S. Nicholson ◽  
...  
Keyword(s):  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Apoptotic Cell ◽  
Intensive Therapy ◽  
Xenograft Model ◽  
Chemotherapeutic Agents ◽  
Cytotoxic Agents ◽  
Sarcoma Cell

Ewing’s sarcoma, characterized by pathognomonic t (11; 22) (q24; q12) and related chromosomal ETS family translocations, is a rare aggressive cancer of bone and soft tissue. Current protocols that include cytotoxic chemotherapeutic agents effectively treat localized disease; however, these aggressive therapies may result in treatment-related morbidities including second-site cancers in survivors. Moreover, the five-year survival rate in patients with relapsed, recurrent, or metastatic disease is less than 30%, despite intensive therapy with these cytotoxic agents. By using high-throughput phenotypic screening of small molecule libraries, we identified a previously uncharacterized compound (ML111) that inhibited in vitro proliferation of six established Ewing’s sarcoma cell lines with nanomolar potency. Proteomic studies show that ML111 treatment induced prometaphase arrest followed by rapid caspase-dependent apoptotic cell death in Ewing’s sarcoma cell lines. ML111, delivered via methoxypoly(ethylene glycol)-polycaprolactone copolymer nanoparticles, induced dose-dependent inhibition of Ewing’s sarcoma tumor growth in a murine xenograft model and invoked prometaphase arrest in vivo, consistent with in vitro data. These results suggest that ML111 represents a promising new drug lead for further preclinical studies and is a potential clinical development for the treatment of Ewing’s sarcoma.

Electron Microscopy of Extraskeletal Neoplasm Resembling Ewing's Sarcoma

1976 ◽  
Vol 34 ◽  
pp. 236-237
Author(s):  
B. N. SUD
Keyword(s):  
Electron Microscopy ◽  
Soft Tissues ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Viable Cells ◽  
Necrotic Tumor ◽  
Poorly Differentiated ◽  
Children And Young Adults ◽  
The Right ◽  
Paravertebral Region

Review of 39 cases of sarcomas involving soft tissues, especially of the lower extremity and paravertebral region of children and young adults, disclosed a uniform histologic picture that was indistinguishable from that of Ewing's sarcoma of bone (1). Biopsy of a soft tissue tumor of the right thigh of a ten year old boy was studied by light microscopy and diagnosed as poorly differentiated sarcoma, probably extra skeletal Ewing's sarcoma (2). A portion of the biopsy was processed for electron microscopy to elucidate the ultrastructural pathology.The specimen revealed a neoplasm, consisting of sheets of viable as well as necrotic tumor cells. The viable cells had a single large rounded, oval or kidney- shaped nucleus with one or more dense nucleoli and chromatin with occasional clumping along the periphery and also in the interior.

Resection of an Ewing’s sarcoma of the right distal humerus

ASVIDE ◽  
2019 ◽  
Vol 6 ◽  
pp. 65-65
Author(s):  
Marco Innocenti ◽  
Elena Lucattelli ◽  
Mattia Brogi ◽  
Francesca Totti ◽  
Domenico Andrea Campanacci
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Distal Humerus ◽  
The Right
Sign in / Sign up

Export Citation Format

Share Document